Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms.

× No keyword cloud information.

4 in total

1. Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis.

Authors: Claudio Cerchione; Ilaria Peluso; Davide Nappi; Anna Emanuele Pareto; Marco Picardi; Vincenzo Martinelli; Fabrizio Pane
Journal: Ann Hematol Date: 2017-02-14 Impact factor: 3.673

2. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

Authors: Novella Pugliese; Claudia Giordano; Davide Nappi; Luigiana Luciano; Claudio Cerchione; Mario Annunziata; Beniamino Casale; Elena Crisà; Maria Rosaria Villa; Luca Pezzullo; Maria Iovine; Marco Picardi; Francesco Grimaldi; Fabrizio Pane; Vincenzo Martinelli
Journal: Cancer Med Date: 2019-04-17 Impact factor: 4.452

Review 3. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.

Authors: Nicola Polverelli; Mirko Farina; Mariella D'Adda; Enrico Damiani; Luigi Grazioli; Alessandro Leoni; Michele Malagola; Simona Bernardi; Domenico Russo
Journal: Cells Date: 2022-02-05 Impact factor: 6.600

4. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.

Authors: Carl C Crodel; Kathleen Jentsch-Ullrich; Marcel Reiser; Lutz Jacobasch; Annette Sauer; Hans Tesch; Thomas Ulshöfer; Regine Wunschel; Francesca Palandri; Florian H Heidel
Journal: J Cancer Res Clin Oncol Date: 2021-11-22 Impact factor: 4.322

4 in total